Gabriel N. Hortobágyi

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Donald Weaver, G Hortobagyi, G N Hortobagyi, G. Hortobagyi, G. N Hortobagyi, G. N. Hortobagyi, G. N. Hortobágyi, G.N Hortobagyi, G.N. Hortobagyi, GABRIEL HORTOBAGYI

1.9K

Publications

138.7K

Citations

186

H-Index

211

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Breast Cancer Care Anderson Hospital University of Michigan

About

Gabriel N. Hortobágyi is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	95	332	36.2K
2	Health Sciences	38	67	6.1K
3	Public Health	10	10	1.5K
4	Engineering	8	8	363
5	Nursing	6	6	243

Gabriel N. Hortobágyi

781

Publications

117.2K

Citations

170

H-Index

Page 1

	Year	Citations
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Journal of Clinical Oncology	2008	2.9K
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer José Baselga, Mario Campone, Martine Piccart, New England Journal of Medicine	2011	2.8K
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, New England Journal of Medicine	2016	1.9K
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Roman Rouzier, Charles M. Perou, W. Fraser Symmans, Clinical Cancer Research	2005	1.9K
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou, Cancer Cell Trastuzumab ResistancePten Activation ContributesMedicinePharmacologyImmunology	2004	1.8K
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation Benjamin D. Smith, Grace L. Smith, Arti Hurria, Journal of Clinical Oncology	2009	1.7K
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy W. Fraser Symmans, Florentia Peintinger, Christos Hatzis, Journal of Clinical Oncology	2007	1.6K
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Kathy S. Albain, William E. Barlow, Steven Shak, The Lancet Oncology 21-Gene Recurrence ScoreBreast OncologyMedicineRandomised TrialPathology	2009	1.4K
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy Henry M. Kuerer, Lisa A. Newman, Terry L. Smith, Journal of Clinical Oncology	1999	1.3K
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Rashmi K. Murthy, Sherene Loi, Alicia Okines, New England Journal of Medicine	2019	1.3K

Page 1